Stay updated with breaking news from Murray Mccutcheon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data show how AbCellera is expanding the reach of T-cell engagers with: CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release...
AbCellera and Biogen Inc. have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in...
Total revenue of $38 million, compared to $485 million in FY 2022Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the yearNet loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022VANCOUVER, Brit...
Total revenue of $7 million, compared to $101 million in Q3 2022Total cumulative partnered program starts of 110, up 20% from Q3 2022Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, respectively, in Q3 2022VANCOUVER, British...
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degraderWILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and A...